The Cancer Diagnostics Revolution | Global Conference 2024

Core Philosophy and Human Factors

• The primary goal of cancer detection is to extend a healthier lifespan rather than immortality.
• A major technological and behavioral hurdle is the human tendency to avoid thinking about cancer until symptoms appear.
• Early-stage cancers are often invisible to patients because immune systems usually manage them; late-stage diagnosis occurs when detection fails.
• Men often delay seeking care due to a reluctance to visit doctors, leading to severe health complications before diagnosis.
• Most patients present for care only after developing symptoms like pain, lumps, or inability to swallow, by which point treatment is often too late for certain "occult" cancers.

Technological Evolution: From Single to Pan-Cancer Detection

• Traditional screening (colonoscopy, mammogram, low-dose CT, PSA) suffers from poor compliance, with 76% of colorectal cancer deaths occurring in the unscreened population.
• "Liquid biopsy" technology detects cancer by analyzing circulating tumor DNA (ctDNA) shed from rapidly turning-over cells into the blood.
• Liquid biopsies are currently used in 40–50% of stage three and four cancer patients to guide treatment without tissue biopsies.
• Technology sensitivity has advanced from detecting stage four cancers to detecting stage one and pan-cancer signatures.
• Future blood tests aim to analyze the entire proteome and metabolome, potentially screening for thousands of diseases beyond cancer during an annual physical.

Clinical Efficacy and Diagnostic Nuance

• False positives in multi-cancer tests do not provide a definitive diagnosis and often trigger a "diagnostic odyssey" involving invasive follow-up procedures that may yield no results.
• Testing is most effective when targeted at high-risk populations stratified by genomic profile, family history, and environmental exposure.
• The "gold standard" for adoption is randomized control trials demonstrating a mortality benefit, not just the ability to downstage cancer.
• Downstaging cancer does not always improve survival; in some cases (e.g., prostate, ovarian), it only extends the duration of living with the disease without altering mortality.
• A study published in The Lancet highlighted the feasibility of these tests while raising unanswered questions regarding their performance in diverse clinical settings.
• Pan-cancer detection must address the reality that some cancers present at advanced stages without a pre-malignant phase, creating "lead time bias" where early detection does not equate to life extension.

Health Equity and Access Barriers

• Over 50% of women do not complete the necessary follow-up steps within 12 months after an abnormal cervical cancer screening.
• Barriers to cervical screening include physical discomfort, sexual trauma triggers, lack of transportation, childcare issues, and confusion regarding screening guidelines.
• One in four women in the US is currently behind on recommended cancer screenings, primarily because they lack awareness of their specific screening needs.
• The Affordable Care Act has insured 35 million more Americans, significantly reducing cancer deaths by facilitating access to care, yet disparities remain.
• Most cancer care (80%) occurs in community hospitals rather than academic centers, necessitating the transfer of expertise to ensure equitable care standards.
• Historical underrepresentation of women and minorities in clinical trials is being addressed by designing studies specifically to include these demographics, resulting in higher enrollment rates.

Policy, Regulation, and Reimbursement

• The National Cancer Institute and US Preventive Services Task Force maintain a conservative stance, requiring mortality-based data before endorsing widespread adoption of new tests.
• Multi-cancer tests currently cost approximately $1,000 per test, creating a risk that only wealthy patients will access them without policy intervention.
• Reimbursement for liquid biopsies has been slow; despite FDA approval and 500 peer-reviewed publications, it took nine years to secure coverage from major insurers for late-stage testing.
• Early detection technologies often increase short-term system costs without immediately lowering overall expenditures, as they expand the population receiving care.
• The US healthcare system lags in adopting new workflows, with 40% of reports still transmitted via fax, hindering the diffusion of new technologies.
• New regulatory pathways, such as the FDA's "Breakthrough Device Program," are being utilized to accelerate market access for life-saving diagnostic tools.

Prevention and Future Outlook

• Prevention strategies, such as the HPV vaccine (which can prevent six types of cancer), face challenges regarding declining vaccination rates and misinformation.
• Screening for cervical and colon cancer is technically "prevention" because it catches pre-disease states, whereas other cancers currently require treatment-based interventions.
• Artificial Intelligence (AI) analyzing electronic medical records can detect subtle cancer signals up to five years before a clinical diagnosis is made.
• "N of 1" trials are emerging to personalize treatment for intractable cases and reverse-engineer survival data from patients who naturally overcame cancer.
• The ultimate goal is to integrate these tests into the standard annual physical, creating a "co-pilot" for primary care physicians.

Panelist Specific Goals and Actions

• GARDEN (Helmi): Aiming for Medicare reimbursement for the first FDA-approved pan-cancer screening test within the current year.
• Teal Health (Cara): Focused on securing FDA approval for an at-home self-collection cervical screening device to reach the 20 million women behind on screenings.
• MSK (Ani): Prioritizing the creation of clinical practice guidelines and demanding more data on downstream mortality outcomes before widespread adoption.
• University of Washington (Larry): Advocating for patient navigators in federally qualified health centers to bridge the gap between technology and underserved communities.
• Prevent Cancer Foundation (Jody): Campaigning to increase collective investment in patient-centered education and ensuring screening recommendations are understood by the public.
• Faster Cures (Greg): Emphasizing that the most effective tool remains social pressure and personal reminders ("ask your loved one if they've been screened").